Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer-Reference-Cited by-同舟云学术

Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer

Published:2003-06-30 Issue:4 Volume:56 Page:305-312
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Yashi Masahiro,Nukui Akinori,Kurokawa Shinsuke,Ochi Masanori,Ishikawa Shinya,Goto Kentaro,Kobayashi Yutaka,Muraishi Osamu,Tokue Akihiko

Publisher

Wiley

Subject

Urology,Oncology

Reference43 articles.

1. Hormone-refractory prostate cancer: a multi-step and multi-event process

2. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault.

3. Neuroendocrine cells in tumour growth of the prostate.

4. Prognostic Significance of Neuroendocrine Differentiation in Prostate Cancer

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma progastrin‐releasing peptide level shows different predictive profiles for treatment response by androgen receptor axis‐targeted agents in patients with metastatic castration‐resistant prostate cancer;Cancer Reports;2022-12-05

Metastatic Castration-Resistant Prostate Cancer with Neuroendocrine Transformation and BRCA 1 Germ-Line Mutation: A Case Report and Literature Review

;OncoTargets and Therapy;2020-08

3. Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: a systematic review and meta-analysis;International Journal of Clinical Oncology;2019-11-25

4. The value of tumor markers in men with metastatic prostate cancer undergoing [ 177 Lu]Lu‐PSMA therapy;The Prostate;2019-10-03

5. Expression and function of gastrin-releasing peptide (GRP) in normal and cancerous urological tissues;BJU International;2014-02-19